Choice of Optimal Transcatheter Treatment for Mitral Insufficiency: 2-Year Real-World Outcomes in the CHOICE MI International Registry

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Consultant Fee/Honoraria/Speaker's Bureau (Personal) - Bayer AG